JNJ logo

JNJ

Johnson & Johnson
HealthcareDrug Manufacturers - GeneralIncome
$227.13 · 15min delay
β 0.26

A high-quality mega-cap income stock trading at a premium valuation. Frameworks sharply disagree on it.

52-wk low $146.1252-wk high $251.71

Mkt Cap

$546.74B

P/E

PEG

2.88

P/B

6.73

Dividend

2.42%

ROE

26.4%

About the business

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Price history

Loading…

Drag across the chart to select a custom period — all analysis below refocuses to that window.

What this means: A significant rerating — the valuation-sensitive frameworks below will have tightened since this move.

Premium view

Normalized peer comparison

Overlay this stock against up to five peers, rebased to 100, with synchronized range switching.

Premium view

What matters now — AI brief

A 90-second summary grounded in Prism's framework scores and the latest price action. Members unlock this automatically.

News & events

Next earnings

Wed, Jul 15 · consensus EPS $2.84 · last actual $2.70

Premium view

Full decision report

Every framework verdict, the structural concerns, the investment case, the decision-boundary levers, and your personal thesis journal — only for members.